Live tape
Top 8, mentions 7d12,493SPCX2,588 mentions▲ +0.08GOOGL2,087 mentions▲ +0.02META1,949 mentions▲ +0.04TSLA1,853 mentions▲ +0.05QQQ1,039 mentions▲ +0.05NFLX1,035 mentions▲ +0.02AMZN978 mentions▲ +0.06NVDA964 mentions▲ +0.07

Equity · Healthcare

RXRX

NASDAQ

Recursion Pharmaceuticals (RXRX)

$3.70 +3.06% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 23, 2026

Reddit mentioned RXRX 13 times in the 30 days to 25 October 2026, across 2 of the communities we track. All of them were scored for sentiment: 69% read bullish, 8% bearish and 23% neither. Reddit data updated 25 October 2026.

Price · Chart
64 sessions
$5 $2 27 Jul 23 Oct

The line runs $3 on 27 July through $3.70 on 23 October, on a scale from $2 to $5. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 64 sessions, 27 Jul – 23 Oct 2026
Market cap $2.0B
52-week range $2.81 – $6.71
Avg volume 1.8M
Mentions · 30d 13
Net sentiment +0.14

as of Oct 23, 2026

Recursion Pharmaceuticals (RXRX) · crowd attention × price

Share ↗
Post on X Share on Reddit Share on LinkedIn
13 mentions

Day16 Oct 2026

MENTIONS10–6 / day
PRICE$3.50$3.0–$5.0
RXRX over the last 30 days, plotting daily Reddit mentions as bars, left-hand scale; the daily closing price as a line on its own right-hand scale, solid across consecutive trading days, held flat and diagonally hatched over days the market was closed.per day0246usd$3.0$3.5$4.0$4.5$5.026 Sep3 Oct11 Oct18 Oct25 Oct
RXRX over the last 30 days, plotting daily Reddit mentions as bars, left-hand scale; the daily closing price as a line on its own right-hand scale, solid across consecutive trading days, held flat and diagonally hatched over days the market was closed.26 Sep11 Oct25 Oct
The Distributed Sentinel 25 Oct 2026

RXRX's busiest day for Reddit mentions was also its highest close of the window — 4 mentions and $4.72 on 5 October

This chart in words

The chart plots daily Reddit mentions of RXRX over the 30 days to 25 October 2026: 13 in total, busiest on 5 October with 4, and 1 on the last day counted. Across this window the close ran between $3.50 on 16 October and $4.72 on 5 October. The line is the daily close over the same window: $3.70 on 28 September, $3.70 on 23 October. Of those days, 20 were trading sessions and the other 10 are hatched on the chart. On 8 of them no session took place, and the last close before it is carried forward rather than plotted; on 2 of them no session took place, and this window holds no earlier close to carry forward.

Recursion Pharmaceuticals (RXRX) on Reddit · 30d

n = 13 scored · Method

In the 30 days to 26 Oct 2026, Recursion Pharmaceuticals drew 13 Reddit mentions in the finance subreddits we track, 13 of them scored for sentiment.

RXRX

69% bullish

Overall market sentiment

54% bullish

RXRX reads 15 points more bullish than overall market sentiment. Same measure; same 30-day window.

Where RXRX is discussed

(30d)
r/wallstreetbets 92% 12 +0.15
r/stocks 8% 1 +0.01

Recursion Pharmaceuticals (RXRX) insider trades

SEC Form 4 · last 90 days · newest reported trade 6 Oct 2026

In the 90 days to 26 Oct 2026, Recursion Pharmaceuticals insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 25 Sep 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 5
Net sold $644K
Non-trade filings 7
Date Insider Type Shares Value
06 Oct 2026 Borgeson Blake Director Sell 50,000 $242K
06 Oct 2026 HERSHBERG ROBERT Director Sell 25,000 $125K
08 Sep 2026 Khan Najat CEO and President Sell 22,408 $79K
01 Sep 2026 Borgeson Blake Director Sell 30,000 $100K
04 Aug 2026 Borgeson Blake Director Sell 30,000 $98K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
06 Oct 2026 HERSHBERG ROBERT Director Option exercise 25,000 $56K
01 Oct 2026 Dar Zavain Director Award 4,607
01 Oct 2026 Li Dean Y Director Award 3,378
15 Sep 2026 Taylor Ben R Chief Financial Officer Tax withheld 5,396 $18K
17 Aug 2026 Hallett David Chief Scientific Officer Tax withheld 26,657 $84K
17 Aug 2026 Khan Najat CEO and President Tax withheld 80,498 $254K
17 Aug 2026 Taylor Ben R Chief Financial Officer Tax withheld 25,018 $79K

Recursion Pharmaceuticals (RXRX) reported financials

SEC EDGAR XBRL SEC EDGAR

Recursion Pharmaceuticals reported revenue of $74.7M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$644.8M.

Figure Reported Period
Revenue $74.7M 31 Dec 2025 fiscal year
Net income −$644.8M 31 Dec 2025 fiscal year
Diluted EPS −$1.44 31 Dec 2025 fiscal year
Total assets $1.2B 30 Jun 2026 at period end
Total equity $915.0M 30 Jun 2026 at period end

Recursion Pharmaceuticals (RXRX) earnings

SEC EDGAR

Recursion Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.25; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.25 $8M
31 Mar 2026 Q1 2026 −$0.22 $6M
31 Dec 2025 FY 2025 −$1.44 $75M
30 Sep 2025 Q3 2025 −$0.36 $5M
30 Jun 2025 Q2 2025 −$0.41 $19M
31 Mar 2025 Q1 2025 −$0.50 $15M
31 Dec 2024 FY 2024 −$1.69 $59M
30 Sep 2024 Q3 2024 −$0.34 $26M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Recursion Pharmaceuticals (RXRX) institutional holders (13F)

SEC Form 13F SEC EDGAR

10 of the 45 institutional funds we track reported a Recursion Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined $194.5M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
ARK Investment Management Held (±25%) +2.8% shares 41,337,632 $151.7M
Marshall Wace Added +63.9% shares 4,714,577 $17.3M
Two Sigma Investments Held (±25%) −17.5% shares 3,353,658 $12.3M
Millennium Management Trimmed −29.8% shares 1,834,762 $6.7M
Man Group Trimmed −36.2% shares 765,786 $2.8M
AQR Capital Management Added +72.7% shares 422,087 $1.5M
Balyasny Asset Management Added +111.7% shares 353,661 $1.3M
Citadel Advisors Trimmed −79.4% shares 128,478 $472K
D. E. Shaw & Co. Held (±25%) −17.6% shares 37,914 $139K
Bridgewater Associates New position 37,667 $138K

Recursion Pharmaceuticals (RXRX) fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 490,129 shares of Recursion Pharmaceuticals failed to deliver (about $2.0M) — the latest of 10 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
30 Sep 2026 490,129 $2.0M 0.092%
29 Sep 2026 627,425 $2.3M 0.117%
28 Sep 2026 782,942 $2.9M 0.146%
25 Sep 2026 470,126 $1.8M 0.088%
24 Sep 2026 242,524 $897K 0.045%
23 Sep 2026 73,931 $299K 0.014%
22 Sep 2026 6,329 $25K 0.001%
21 Sep 2026 2,726,286 $10.4M 0.509%
18 Sep 2026 9,853 $35K 0.002%
17 Sep 2026 1,996,570 $6.4M 0.373%
14 Sep 2026 497,478 $1.6M 0.093%
10 Sep 2026 400,138 $1.3M 0.075%

Recursion Pharmaceuticals (RXRX): frequently asked questions

From live data

Have Recursion Pharmaceuticals insiders bought or sold shares recently?

In the 90 days to 26 Oct 2026, Recursion Pharmaceuticals insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 25 Sep 2025, show no open-market purchase. A further 7 filings were grants, awards, gifts or exercises rather than open-market trades.

How many institutions hold Recursion Pharmaceuticals?

10 of the 45 institutional funds we track reported a Recursion Pharmaceuticals position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Recursion Pharmaceuticals had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Recursion Pharmaceuticals is dated 30 Sep 2026, when 490,129 shares failed to deliver.

When did Recursion Pharmaceuticals last report earnings?

Recursion Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.25; no next date is announced in SEC filings yet.

What exchange is Recursion Pharmaceuticals listed on?

Recursion Pharmaceuticals trades on NASDAQ under the ticker RXRX.

What is Reddit saying about Recursion Pharmaceuticals?

Recursion Pharmaceuticals was mentioned 0 times in the last 7 days across the finance subreddits we track, and 13 times over the trailing 30 days. Of 13 classified mentions, 69% read bullish, 8% bearish and 23% neutral. Crowd sentiment is a social signal, not investment advice.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. RedditReddit ingest across the tracked finance subreddits
  4. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  5. SEC EDGARSEC EDGAR 13F filings
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARValuation computed from SEC EDGAR filings